2,167 Shares in Krystal Biotech, Inc. $KRYS Acquired by Summit Global Investments

Summit Global Investments purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,167 shares of the company’s stock, valued at approximately $805,000.

Other institutional investors have also made changes to their positions in the company. Royal Bank of Canada raised its position in shares of Krystal Biotech by 145.2% in the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after acquiring an additional 964 shares during the period. AQR Capital Management LLC raised its stake in Krystal Biotech by 29.9% during the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after buying an additional 2,792 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Krystal Biotech by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after acquiring an additional 688 shares in the last quarter. Empowered Funds LLC acquired a new position in Krystal Biotech in the first quarter valued at about $218,000. Finally, Cetera Investment Advisers increased its holdings in shares of Krystal Biotech by 107.9% in the second quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock worth $597,000 after acquiring an additional 2,255 shares in the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on KRYS. Bank of America boosted their price objective on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. HC Wainwright upped their price target on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a report on Tuesday, June 16th. Jefferies Financial Group reissued a “buy” rating and set a $474.00 price objective on shares of Krystal Biotech in a research report on Monday, July 13th. Royal Bank Of Canada started coverage on shares of Krystal Biotech in a report on Friday. They set an “outperform” rating and a $400.00 price objective on the stock. Finally, Evercore reaffirmed an “outperform” rating and issued a $300.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $365.40.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares of the company’s stock, valued at $347,270. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This represents a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 51,642 shares of company stock worth $16,471,923. Insiders own 13.10% of the company’s stock.

Krystal Biotech Stock Up 1.2%

Shares of KRYS opened at $332.27 on Friday. Krystal Biotech, Inc. has a twelve month low of $136.73 and a twelve month high of $382.54. The stock has a market capitalization of $9.83 billion, a P/E ratio of 41.64 and a beta of 0.53. The company has a 50 day moving average of $344.39 and a 200-day moving average of $299.25.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The business had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 7.68 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.